|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
Q2 FY2021
As of Sep 30, 2020
|
Q1 FY2021
As of Jun 30, 2020
|
Q4 FY2020
As of Mar 31, 2020
|
Q3 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Sep 30, 2019
|
Q1 FY2020
As of Jun 30, 2019
|
Q4 FY2019
As of Mar 31, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Accounts receivable - related party | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted Cash (Escrow) | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses and other receivables | ||||||||||||||||||||
| VAT receivable | ||||||||||||||||||||
| Deposit on foreign exchange contract | ||||||||||||||||||||
| Receivable from related parties | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net of accumulated depreciation | ||||||||||||||||||||
| Intangible assets, net of accumulated amortization | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Foreign currency contract | ||||||||||||||||||||
| Due to related party | ||||||||||||||||||||
| Other liabilities and accrued expenses | ||||||||||||||||||||
| Notes payable, current portion | ||||||||||||||||||||
| Payable to related parties | ||||||||||||||||||||
| Deferred revenue, current portion | ||||||||||||||||||||
| Foreign exchange contract derivative liability | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Notes payable, non-current portion | ||||||||||||||||||||
| Deferred revenue, non-current portion | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Common stock, $0.001 par value, 42,000,000 shares authorized and 28,899,402 shares issued and outstanding at December 31, 2023 and March 31, 2023 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ (deficit) equity | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
Loading...
